NASDAQ:TOI Oncology Institute (TOI) Stock Price, News & Analysis $0.29 0.00 (0.00%) (As of 09/11/2024 ET) Add Compare Share Share Today's Range$0.28▼$0.3050-Day Range$0.29▼$0.5652-Week Range$0.27▼$2.66Volume66,347 shsAverage Volume153,389 shsMarket Capitalization$21.46 millionP/E RatioN/ADividend YieldN/APrice Target$2.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Oncology Institute alerts: Email Address Oncology Institute MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside767.2% Upside$2.50 Price TargetShort InterestHealthy0.74% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.31Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.63) to ($0.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.90 out of 5 starsMedical Sector575th out of 910 stocksOffices & Clinics Of Medical Doctors Industry4th out of 7 stocks 3.5 Analyst's Opinion Consensus RatingOncology Institute has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageOncology Institute has received no research coverage in the past 90 days.Read more about Oncology Institute's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.74% of the float of Oncology Institute has been sold short.Short Interest Ratio / Days to CoverOncology Institute has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oncology Institute has recently increased by 9.55%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOncology Institute does not currently pay a dividend.Dividend GrowthOncology Institute does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TOI. Previous Next 1.5 News and Social Media Coverage News SentimentOncology Institute has a news sentiment score of -0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Oncology Institute this week, compared to 3 articles on an average week.Search Interest1 people have searched for TOI on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oncology Institute insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.50% of the stock of Oncology Institute is held by insiders.Percentage Held by InstitutionsOnly 36.86% of the stock of Oncology Institute is held by institutions.Read more about Oncology Institute's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Oncology Institute are expected to grow in the coming year, from ($0.63) to ($0.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncology Institute is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncology Institute is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncology Institute has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Oncology Institute's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchExpert Who Predicted Lehman Collapse Issues Major New WarningHow The Boeing Disasters Could Hit Nvidia Investors You may have heard about Boeing planes falling apart midflight and catching fire. But, according to analyst Dan Ferris, there's something much darker going on here that could threaten Nvidia, the Magnificent 7, and the entire U.S. stock market.Click here for the full story. About Oncology Institute Stock (NASDAQ:TOI)The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.Read More TOI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TOI Stock News HeadlinesSeptember 10 at 5:49 AM | msn.comAncient viruses in the body help cancer cells to grow finds breakthrough researchSeptember 8, 2024 | msn.comImmunotherapy before and after lung cancer surgery reduces death risk and disease recurrence, research findsSeptember 12, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaWhoever wins the presidential election – Trump or Harris – this energy surprise could see their popularity skyrocket… as a new period of wealth and prosperity sweeps across the nation… emanating from the last place anyone could have predicted. Now, billions of dollars are amassing behind this force, with everyone from Jeff Bezos and Bill Gates to Sam Altman and Warren Buffett pouring their money into this phenomenon.September 7, 2024 | msn.comUnderstanding sarcoma: A guide for parents and new advances in treatmentSeptember 6, 2024 | msn.comWake Forest University researchers to send lab-grown organs to space for cancer researchSeptember 6, 2024 | msn.comNovel study reveals how aging immune system fuels cancer growth, potentially opening new avenues for preventionSeptember 4, 2024 | msn.comTwo-in-one treatment could hold promise for incurable brain cancer, mouse study showsAugust 31, 2024 | msn.comJamia’s groundbreaking AI database set to transform oral cancer diagnosisSeptember 12, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaWhoever wins the presidential election – Trump or Harris – this energy surprise could see their popularity skyrocket… as a new period of wealth and prosperity sweeps across the nation… emanating from the last place anyone could have predicted. Now, billions of dollars are amassing behind this force, with everyone from Jeff Bezos and Bill Gates to Sam Altman and Warren Buffett pouring their money into this phenomenon.August 31, 2024 | msn.comLocal manufacturing process ups cancer risk among smokeless tobacco users, finds studyAugust 28, 2024 | msn.com‘Breast cancer is a female problem. Is the doc lying? People would ask’August 28, 2024 | msn.comAll work and all study help Bengaluru girl shine in NEET-PGAugust 16, 2024 | msn.com6 little changes in everyday routine reduce the risk of cancerAugust 16, 2024 | msn.comU of I getting almost $33M in cancer research fundsAugust 15, 2024 | msn.comRun organised at Besant Nagar to spread cancer awarenessAugust 15, 2024 | latimes.comUSC Norris Comprehensive Cancer Center to Open Radiation Oncology and Imaging Center in Newport BeachAugust 14, 2024 | msn.comRole of inflammation in gastrointestinal tumor developmentAugust 14, 2024 | seekingalpha.comThe Oncology Institute, Inc. (TOI) Q2 2024 Earnings Call TranscriptSee More Headlines Receive TOI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncology Institute and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/11/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Offices & clinics of medical doctors Sub-IndustryHealthcare Current SymbolNASDAQ:TOI CUSIPN/A CIK1799191 Webtheoncologyinstitute.com Phone562-735-3226FaxN/AEmployees660Year FoundedN/APrice Target and Rating Average Stock Price Target$2.50 High Stock Price Target$2.50 Low Stock Price Target$2.50 Potential Upside/Downside+767.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-83,070,000.00 Net Margins-18.86% Pretax Margin-19.86% Return on Equity-136.63% Return on Assets-33.56% Debt Debt-to-Equity Ratio3.08 Current Ratio3.31 Quick Ratio2.99 Sales & Book Value Annual Sales$361.07 million Price / Sales0.06 Cash FlowN/A Price / Cash FlowN/A Book Value$0.77 per share Price / Book0.37Miscellaneous Outstanding Shares74,438,000Free Float67,366,000Market Cap$21.46 million OptionableNot Optionable Beta0.61 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Richard Alan Barasch (Age 70)Chairman of the Board Dr. Daniel Virnich FACHE (Age 45)M.D., MBA, Chief Executive Officer Comp: $614.62kMr. Mihir Arunkumar Shah CPA (Age 46)Chief Financial Officer Comp: $505.13kDr. Yale D. Podnos F.A.C.S. (Age 52)M.D., M.P.H., Chief Medical Officer Comp: $535.36kMr. Jeremy N. Castle M.B.A. (Age 40)Chief Operations Officer Mr. Mark Hueppelsheuser Esq.General CounselMr. Jordan McInerneyChief Development OfficerMore ExecutivesKey CompetitorsEnzo BiochemNYSE:ENZExagenNASDAQ:XGNPono Capital TwoNASDAQ:PTWOBurning Rock BiotechNASDAQ:BNRATI Physical TherapyNYSE:ATIPView All CompetitorsInsiders & InstitutionsRenaissance Technologies LLCBought 199,300 shares on 8/9/2024Ownership: 0.456%Tiff Advisory Services LLCBought 995,280 shares on 8/7/2024Ownership: 1.906%Havencrest Healthcare PartnersSold 8,637 sharesTotal: $18,310.44 ($2.12/share)Havencrest Healthcare PartnersSold 6,979 sharesTotal: $14,935.06 ($2.14/share)Havencrest Healthcare PartnersSold 24,915 sharesTotal: $57,304.50 ($2.30/share)View All Insider TransactionsView All Institutional Transactions TOI Stock Analysis - Frequently Asked Questions How have TOI shares performed this year? Oncology Institute's stock was trading at $2.04 on January 1st, 2024. Since then, TOI shares have decreased by 85.9% and is now trading at $0.2883. View the best growth stocks for 2024 here. How were Oncology Institute's earnings last quarter? The Oncology Institute, Inc. (NASDAQ:TOI) issued its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.07. The firm had revenue of $98.58 million for the quarter, compared to analysts' expectations of $103.31 million. Oncology Institute had a negative trailing twelve-month return on equity of 136.63% and a negative net margin of 18.86%. Who are Oncology Institute's major shareholders? Oncology Institute's top institutional shareholders include Tiff Advisory Services LLC (1.91%) and Renaissance Technologies LLC (0.46%). Insiders that own company stock include Brad Hively, Richard A Barasch, Richy Agajanian, Matthew P Miller, Mohit Kaushal and Havencrest Healthcare Partners. View institutional ownership trends. How do I buy shares of Oncology Institute? Shares of TOI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TOI) was last updated on 9/12/2024 by MarketBeat.com Staff From Our PartnersInvest before this deal closes on 9/18This company can create aviation fuels from waste, they qualify to help airlines meet net-zero carbon pledges ...Deal Maker | SponsoredHow to grow a small trading account into a $100k? Why is Warren Buffett dumping stocks? Billionaires like Warren Buffett, Tim Cook, and Jeff Bezos are offloa...Timothy Sykes | SponsoredWarning For Nvidia HoldersHow The Boeing Disasters Could Hit Nvidia Investors You may have heard about Boeing planes falling apart mi...Stansberry Research | SponsoredHidden Agenda Behind Government’s Operation Cash ControlRemember all the prodding to give up cash and shift to electronic payments instead? "Ease of use!" was thei...Weiss Ratings | SponsoredJeff Bezos Just Humiliated Elon MuskThe Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next...InvestorPlace | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredRecently listed NASDAQ firm is well positioned for growth with game-changing AI platform for e-commerce.With an innovative AI platform, one tiny but growing NASDAQ firm is ushering in a new e-commerce era and is tr...Smallcaps Daily | SponsoredThe $15 Stock Powering NVIDIA, TESLA and MicrosoftThe Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known suppl...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding The Oncology Institute, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncology Institute With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
